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20 ABSTRACT: The dinuclear photo-oxidizing RuII complex [{Ru(TAP2)}2(tpphz)]4+ (TAP = 1,4,5,8- tetraazaphenanthrene, tpphz = 
21 tetrapyrido[3,2-a:2′,3′-c:3′′,2′′- h:2′′′,3′′′-j]phenazine), 14+ is readily taken up by live cells localizing in mitochondria and nuclei. 
22 In  this  study,  the  two-photon  absorption  cross-section  of  14+   is  quantified  and  its  use  as  a  two-photon  absorbing 
23 phototherapeutic is reported.  It was confirmed that the complex is readily photo-excited using near infrared, NIR, light 
24 through two-photon absorption, TPA. In 2-D cell cultures, irradiation with NIR light at low power results in precisely focused 
25 photo-toxicity effects in which human melanoma cells were killed after 5 minutes of light exposure.  Similar experiments 
26 were then carried out in human cancer spheroidsthat provide a realistic tumor model for the development of therapeutics 
27 and phototherapeutics. Using the characteristic emission of the complex as a probe, its uptake into 280 µm spheroids was 
28 investigated  and  confirmed  that  the  spheroid  takes  up  the  complex.  Notably  TPA  excitation  results  in  more intense 
29 luminescence being observed throughout the depth of the spheroids, although emission intensity still drops off toward the 
30 necrotic core. As 14+ can directly photo-oxidize DNA without the mediation of singlet oxygen or other reactive oxygen species, 
31 photo-toxicity within the deeper, hypoxic layers of the spheroids was also investigated. To quantify the penetration of these 
32 phototoxic effects, 14+ was photo-excited through TPA at a power of 60 mW, which was progressively focused in 10 µm steps 
33 throughout the entire z-axis of individual spheroids. These experiments revealed that, in irradiated spheroids treated with 






40 The potential of photodynamic therapy, PDT, as a possible 
41 treatment regime was first identified over a hundred years 
42 ago, 1-3 but it only became clinically available from the 
43 1980s.3-8 This light driven modality requires a 
44 photosensitizer, PS, which is essentially a prodrug. 9-12 In fact, 
45 photo-excitation of the PS results in the generation of 
46 reactive molecular species and it is these species that are 
47 responsible  for  the  therapeutic  action  of  PDT;  they  are 
48 created by two common pathways,13-15  both of which  begin 
49 with the PS excited into a triple state. 
50 In Type I reactions, the photo-excited PS participates in 
51 redox  processes  leading  to  generation  of  reactive oxygen 
52 species (ROS) that trigger cell death. 16  On the other hand, 
53 Type-II reactions involve the direct energy transfer from the 
54 triplet state of the PS to dioxygen thus forming highly 
55 reactive singlet oxygen (1O2), that is capable of damaging 
56 virtually all biomolecules17-19 
57 PDT is still an emerging treatment technique. Consequently, 
58 although PS leads are in development, only a few systems are 
59 currently  licensed.  10,20  Nevertheless,  PDT  offers particular 
potential for the treatment of skin cancers.21-23 However, 
whilst some FDA-approved PS molecules have been tested in 
preclinical melanoma models demonstrating tumor 
regression and prolonged survival rates,24,25 remission and 
reoccurrence of melanoma have also been reported.26-28 Full 
clinical trials on the treatment of choroidal melanoma and 
metastatic skin melanoma using a clinically established 
sensitizer Verteporfin, and also Chorin e6, have been 
reported and photo-excitation at fluences of 100- to 120 
J/cm2 produced promising therapeutic responses.29,30 
However, one of the complications with classical PDT 
regimes arises from hypoxia. Due to rapid growth many 
tumors possess hypoxic regions, particularly at, and close to, 
their core.31 Hence, incomplete treatment of tumors by PDT 
leading to relapse often involves these hypoxic regions 
where phototoxic effects are diminished. 32 
A second potential drawback to current PDT modalities used 
in treating solid cancers is poor selectivity toward cancer 
cells. One approach to improve tumor tissue targeting over 
normal stroma is to activate a PS through two-photon 
absorption, TPA. As this requires the absorption of two 
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proportional to the square of the light source intensity and 
1 therefore only occurs at, or very close to, the focal point of 
2 the laser.33 TPA also has an added advantage of providing a 
3 method to excite the PS in the near-infrared, NIR, therapeutic 
4 window where biological materials are most transparent, 
5 thereby providing PDT up to depths of 8 mm.34 However, this 
6 requires a PS with an appreciable two photon absorption 
7 cross section, TPACS (σ) and unfortunately, current 
8 commercial PS molecules have low TPACS; for example for 
9 photofrin, σ = 3 BM at 800 nm, 35 which results in low 
10 therapeutic effects under two photon irradiation 
11 conditions.36,37 
12 An ideal PS should be amphipathic in nature, so that it can 
13 readily transverse the cellular membrane but display good 
14 water-solubility, exhibit a minimum toxicity in the dark, and 
15 be  photostable.  38,39    Additionally,  a  good  TPACS  would 
16 enhance treatment depths within tumors. 34,40 It is becoming 
17 apparent that these demanding criteria can be met by certain 
18 transition metal complexes; 41. The fact that complexes of d6- 
19 metal centers can display large optical nonlinearity is well 
20 established. 42-44.   At the same time, this class of  complexes 
21 have been investigated as photosensitizers for PDT, 45-48 with 
22 RuII  complexes attracting particular attention. 49-53. In recent 
23 work the potential of d6 complexes for TPA-PDT has also been 
24 delineated. 41,54-59 
25 In separate research, it has been found that new cancer 
26 treatments often fail clinical trials even after successful 
27 preclinical studies. 60,61 This is attributed to the fact that pre- 
28 clinical models usually involve either 2D cell cultures or 
29 animal models. 2D monolayer models are not capable of 
30 mimicking the complexity and heterogeneity of clinical 
31 tumors, 62,63 while in vivo tumors models involving non- 
32 human species can display discrepancies due to physiological 
33 differences between species. In response to these 
34 difficulties, humanized 3D models64 are being developed; in 
35 particular, multicellular spheroids possess several features of 
36 in vivo tumors such as cell-cell interaction, hypoxia, drug 
37 penetration, response and resistance, and 












50 Figure 1. Structure of complex 14+. 
51 As part of a program to identify novel therapeutics70-73 and 
52 phototherapeutics74,75 based on d6-metal complexes, we 
53 recently reported on a novel dinuclear RuII complex 
54 [{Ru(TAP)2}2(tpphz)]4+, 14+, Figure 1, (TAP = 
55 tetraazaphenanthrene, tpphz = tetrapyridophenazine) that 
56 binds to duplex and quadruplex DNA with high affinities.76 
57 This complex is water-soluble, stable in serum free media, 
and is internalized into live cells, where it predominately 
localizes in the nucleus and mitochondria of melanoma cells. 
Earlier studies have established that complexes containing 
electron deficient RuII(TAP)2 units possess strongly oxidizing 
RuII→TAP 3MLCT excited states capable of directly photo- 
oxidizing guanine sites within DNA.77-82 In agreement with 
these previous reports, detailed photophysical studies on 14+ 
revealed that both quadruplex and duplex DNA quench its 
excited state and this results in the generation of photo- 
oxidized guanine radical cation sites within the DNA. 
Furthermore, within 2-D melanoma cultures, we found that 
whilst 14+ is not intrinsically cytotoxic, it is activated by light; 
for example, irradiation with low fluences of LED light at 405 
nm rapidly induced apoptosis in human C8161 melanoma 
cells, effectively resulting in zero cell-viability. 76 
Complex 14+ was developed as a photo-redox active analogue 
of the metal complex [{Ru(phen)2}2(tpphz)]4+ (phen = 
phenanthroline) which has been successfully used as a live 
cell TPA optical imaging probe.83 Given that 14+ is capable of 
directly damaging biomolecules without the mediation of 1O2 
or other ROS, that it localizes in both nuclei and 
mitochondria, which are specific targets for PDT,9,48,84,85 and 
the fact that it is related to a system with an appreciable 
TPACS, we reasoned that this complex could be developed as 
a PS to initiate PDT effects at tissue depths where hypoxic 
occurs and normal PDT regimes are ineffective. 
Herein, we report that 14+ functions well as a PS in TPA 
conditions and as a consequence the complex facilitates high 
spatial resolution phototoxicity within an engineered 
spheroid model of the highly invasive and spontaneously 
metastatic, recalcitrant human skin cancer, C8161 
melanoma.28 Furthermore, as the complex is luminescent, 
and its emission properties are compatible with optical 
microscopy, we can directly track the penetration of this 
theranostic deep into this tumor model. 
Virtually no studies on metal complex photosensitizers and 
spheroids have been reported. The Chao group recently 
reported on RuII-complexes for TPA-PDT in HeLa-based 
spheroids but their work involved PSs that function through 
a classic oxygen-dependent Type II mechanism, whereas the 
photo-damaging mechanism of 14+ is independent of ROS 
and 1O2. As the employed spheroid model contain healthy, 
hypoxic, and necrotic layers these studies have afforded 
insights into the effectiveness of the new PS in a realistic 
tumor environment containing both quiescent and 
proliferative areas. Consequently, the use of this preclinical 
human tumor model has provided detailed information on PS 
penetration, light penetration, responsiveness dosage and 
resistance area that could only previously be obtained by 
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14 Figure 2. Emission from 14+ internalized within human 
15 melanoma cells following a TPA laser excitation over a 
16 wavelength range of 840 -1000 nm and power range of 5 – 40 
17 mW (Scale Bar =10µm). 
18 We first investigated the TPACS of 14+ through an adaption of 
19 a previously reported method86  (see Materials and Methods 
20 for details). This led to an estimate maximum TPACS of σ = 
21 90 GM, which is up to double that of commercial sensitizers 
22 that have been investigated for TPA-PDT.87 88 
23 
24 We then went on to investigate emission within the 
25 melanoma cells using TPA conditions, which revealed 
26 optimal emission outputs from the internalized complex on excitation at 850 - 900 nm (Figure 2), confirming that it could 
be photo-excited in these conditions using NIR light, well 
28 within the therapeutic window. 
29 
30 The TPA-PDT potential of 1
4+ was next investigated in a 
31 monolayer of human C8161 melanoma cells incubated  with 
32 100 µM of 1
4+ for 24 hour to ensure complete internalization. 
33 A discrete 250x250 pixel region of interest (ROI) was marked 
34 in a 512x512 pixel frame and irradiated with 900 nm laser light (10 and 20 mW). The ratio of live and dead cells were 
determined   before   and   after   the   irradiation   (every   5 
36 minutes) using Syto-9 (cell indicator) and PI as live and dead 
37 cell markers respectively - see SI and Figure 3. This 
38 experiment revealed that at 10mW, 30min exposure time 
39 was required before any phototoxicity was observed in 
40 irradiated cells within the ROI (see SI), while at 20mW the 
41 entire ROI showed complete melanoma death after 5 
42 minutes of exposure – Figure 3. The photoxic-effect was 
43 observed in melanoma cells only in the presence of Ru-Ru 
44 TAP, and not in response to two-photon-laser irradiation 
















Figure 3. Two-photon photo-toxicity of 14+ in human melanoma 
cells treated with 14+ (100 μM) after irradiation within the 
marked white square at 900nm. Live/dead cells imaged with Left 
column: Syto-9 (2 µM), Middle column: Propidium iodide (500 
nM), and Right column: combined image. Recorded at 0 mins 
(top row), 5 mins (middle row), and 10 mins (bottom row) (scale 
bar = 20 µm). 
Apoptosis and necrosis are cell death defined responses to a 
stimulus. In response to Ru(II) plus light activation cell death 
was studied as apoptosis more specifically using Annexin V 
and propidium iodide (PI). Furthermore, morphology 
changes of cells (by H and E) and cytoskeleton filament (F- 
actin) structures were also studied. Both apoptosis and 
necrosis was noticed within the cell population after PDT 
treatment. Cell size was decreased, actin filaments were 
damaged, with shrinkage in nuclear size and cell blebbing, 
suggesting necrosis as the prominent cause of death (See SI). 
We have previously established that C8161 human 
melanoma spheroids cultured for 10 days (at an initial 
seeding density of 12,000 cells) have an outer proliferative 
area of approximately 100 µm in depth over a second layer 
of hypoxic cells that is also approximately 100 µm thick. The 
remaining central volume of the spheroid forms a necrotic 
core.89 These features provide an opportunity to study the 
PDT effect of 14+ in a live multicellular 3-D tumor model that 
has both proliferative and hypoxic regions and thus assess 
the therapeutic effectiveness of this PS in low oxygen 
conditions. In these experiments we first explored photo- 
excitation of 14+ at various depths within tumor spheroids 
using conventional one-photon excitation at 458 nm and 
two-photon excitation (λex = 900nm). Although 
luminescence was observed throughout the 280 x 280 µm 
spheroid, indicating that the complex penetrates deep into 
the spheroids, emission intensity using either excitation 



















10 Figure 4 Comparing the luminescence of 14+ in a 280 ✕ 280 µm 
11 C8161 human melanoma spheroids following: (A) one-photon 
12 excitation (458 nm) and (B) two-photon excitation (900 nm) at a 
13 power of 10 mW. Intensities measured at z-stack depths of: (i) 0 
14 µm, (ii) 60 µm, (iii) 180 µm, and (iv) 240 µm. (scale bar = 100 µm). 
15 This decrease in signal is probably caused by a combination 
16 of two effects:1) there is a concentration gradient for the 
17 complex that diminishes with spheroid depth and/or 2) light 
18 penetration into the center of the spheroid is too low to 
19 photo-excite 14+. Nevertheless, a comparison of emission 
20 produced by 1PA and TPA at analogous laser powers reveals 
21 that, as expected, NIR excitation results in higher intensity 


















photoexcitation of the complex to a depth of ~240 ± 20 µm 




Figure 5. Two-photon PDT in a human melanoma spheroid outer 
proliferative area region with a 900 nm laser and powers of: (A) 
40 and (B) 60 mW after treatment with 100 µM of 14+ for 24 
hours. Left: live cells imaged with Syto-9. Right: dead cells 
imaged with PI. In spheroids untreated with 14+, illumination at 
either power produced no increase in cell death (scale bar = 
20µm) 
40 Figure 6. Figure 6. TPA-PDT on human melanoma spheroids cultured for 10 days. Spheroids were then allowed to settle on a 35mm plate 
41 overnight and incubated with 14+ (100uM), propidium iodide (500nM) and Syto-9 (2µM) in SFM for 24 hours. Spheroids were irradiated 
42 with a 900nm laser (power = 60mW) using a continuous z-stack scan (10µM apart) for 30 min. This was followed by a live and dead cell 
43 scan through the whole spheroid. Live/dead scan at specific depths before treatment revealing hypoxic/necrotic central region (before 
44 treatment, top). Analogous live/dead scans 15 minutes (middle) 30 minutes (bottom) after irradiance. (scale bar = 50 µm). 
45 Consequently, the therapeutically effective dose of 14+ in 
46 melanoma spheroids using a two-photon excitation regime 
47 was evaluated. In particular, the effect of laser power on 
48 exposure to 14+ at a concentration of 100 µM was quantified. 
49 Initially excitation through laser irradiation at 900 nm was 
50 focused  on the spheroid outer proliferative layer  at fluxes of 
51 20,  40  and  60  mW  respectively.  Live  and  dead  cells were 
52 quantified before irradiation and then at every 15 minutes 
53 using Syto-9 and PI respectively – Figure 5. 
54 These experiments showed that although no cell death 
55 occurred at 20 mW flux, at 40mW the proliferative region of 
56 the spheroid was eradicated after 30 to 45 min of exposure, 
57 Figure 5a, and irradiation at 60 mW produced the same effect 
after only 15 minutes of light exposure – Figure 5b. Negative 
control experiments confirmed that spheroids untreated with 
14+ showed no increase in cell death on laser irradiation 
confirming that the photo-sensitization of the spheroids 
requires 14+. The differences in the irradiance dose for 
monolayer cultures compared to melanoma spheroids 
illustrates how the use of 3D spheroids provides an improved 
preclinical model for lead development. 
Next we investigated the depth of the phototherapeutic effect 
of 14+ within the spheroid. Depending on cancer stage, human 
melanoma tissue thickness can vary, consequently PDT 
treatment will be optimized when a PS penetrates and 
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point on the surface of the spheroid was chosen and then laser 
1 irradiation at a power of 40 mW or 60 mW was focused at z- 
2 axis depths that progressively increased in 10 µm steps (Figure 
3 6 and SI). Again, the ratio of live and dead cells in this z-stack 
4 was determined before irradiation and every 15 minutes 
5 thereafter using Syto-9 and PI. At 40 mW laser power, minimal 
6 evidence of phototoxicity at depth was observed after 30 to 45 
7 min, but at 60 mW the continuous z-stack scan revealed cell 
8 death  within  15  to  30  minutes.  Significantly,  although  the 
9 phototoxic effect was at its greatest between 0 to 80 µm, cell 
10 death was observed throughout the entire z-axis depth of the 
11 spheroid - Figure 6C, showing that cell killing occurred in the 
12 hypoxic regions of the spheroid. A similar analysis of light- 
13 induced cell death across the entire 300x300 µm x-y plane at 
14 60 mW revealed that phototoxic effects can be seen through 
15 the entire xy plan, even at depth. 
16 Conclusion 
17 
18 Lamp light sources commonly used for conventional PDT are in an 
19 energy range of 60 to 200 J/cm2 (commonly with flux rates of 
20 150 mW/cm2). 90 Although a high flux rate does reduce 
21 treatment time, it often causes hyperthermia and a reduced 
22 photodynamic effect due to oxygen depletion. 91-94 
23 Furthermore, although lamp sources are suitable for 
24 treatment of large skin area they cannot be focused on small specific lesions. In contrast, as laser excitation volumes of a few 
femtoliters  can  be  attained  by  two-photon  excitation, high 
26 spatial selectivities can be obtained providing the potential to 
27 selectively treat melanoma without deleterious effects on 
28 surrounding tissue. Furthermore, excitation of a PS through 
29 TPA at 900 nm avoids a known mechanism of PDT resistance in 
30 melanoma;  the  abundance  of  melanin  in  such  pigmented 
31 tumors means that light that should excite the PS is instead 
32 absorbed by melanin.26,95,96 This “filter” effect means that 
33 transmittance through melanoma only occurs at wavelength 
34 about 700 nm.27,97 
35 In summary, given that NIR photo-excitation of 14+ through TPA 
36 allows phototoxic effects to be delivered with high precision 
37 into the depths of a therapeutically relevant and realistic 
38 tumor model to induce cell death even in hypoxic conditions, 
39 this complex is a highly promising lead for focused PDT 
40 regimes. By exploiting structural “ground rules” used to 
41 optimize TPACS, 33,57  new derivatives of this lead complex with 
42 enhanced   two-photon   excitation   properties   are currently 
43 being targeted. Ongoing work exploring the use of this PS in 
44 more sophisticated preclinical models will form the basis of our 
45 future reports. 
46 
47 Material and Method 
48 Complex 14+ was synthesized through a reported method76 
49 Estimate of two-photon absorption cross-section 
50 The value of two-photon absorption cross-section was 
51 calculated according to the following modified equation 
52 presented by Rebane and co-workers86 
53 
54 σs = (cr/cs )*()Is/Ir)*(Fl λs/Fl λr)*(∑ lr/∑Fls)*(φrφs)* σr (1) 
55 where σ is the two-photon absorption cross-section, I is two 
56 photon intensity, Fl (one photon emission intensities at l) ∑Fl is 
57 the integrated one photon intensity, c is the molar 
concentration (r,s are reference and sample), and ϕ is the 
differential emission quantum yield in the spectral range: 608- 
620 nm. The differential emission quantum yield of Rhodamine 
B, was taken as 0.5. The value σr for Rhodamine B in MeOH was 
taken as 180 GM at 850 nm and 13 GM at 900 nm. 86 The 
differential quantum yield ϕ was obtained on a Jobin-Yvon 
Fluoromax 4 fluorimeter under one photon excitation. 
However, in order to achieve good spectral agreement for the 
reference under one- and two photon excitation, a lower 
solution concentration required for single photon 
measurements. The emission maxima and QY of Rhodamine B 
in MeOH is known to vary with sample concentration 
Therefore, the two-photon absorption cross section were 
calculated using Rhodamine B QY which corresponds to the 
solution used i) for two-photon measurements (QY = 0.4[5]) 
and ii) for single photon measurements (QY= 0.65[5]). The 
difference  between  the  two  calculations  are  
approximately 50%. Thus a range of ~ 7 (@ 900 nm) to 90 
(@850 nm) GM was estimated. These errors are due to several 
factors including the small values and uncertainties of 
rhodamine B two-photon cross section at 900 nm (which is 13 
GM). 
Human melanoma cell culture 
The C8161 human melanoma cell line was isolated from an 
abdominal wall metastasis from a recurrent malignant 
melanoma menopausal woman (and a gift from Professor F. 
Meyskens UC Irvine (USA) via Dr. M. Edwards (University 
Glasgow, UK)). C8161 melanoma cells were grown in 
melanoma culture medium consisted of EMEM media (Sigma- 
Aldrich) supplemented with FCS (10%v/v), L-glutamine (2uM), 
Pencillin (100U/mL), streptomycin (100ug/mL) and 
Amphotericin (0.625ug/mL). 
Intracellular localization in human melanoma cell line 
C8161 melanoma cells were grown in 6-well plates for 24 hours 
at 37˚C. The cells were washed with SFM and incubated with 
100 µM RuRuTAP for 1, 6, 12 and 24 hours in dark at 37˚C. For 
mitochondria, nucleus and lysosome co-localisation, the cells 
were further incubated with Mitotracker (200 nM), 
Lysotracker (100 nM) and DAPI (300 nM, for 15min) for an 
hour. Cells were washed with SFM and fixed with 
formaldehyde (3.7%, 15 min). Cell imaging was performed 
after cells were washed with PBS (thrice, 5min). 
Photo-cytotoxicity using 405±20nm lamp in human 
melanoma cell line 
C8161 melanoma cells were grown in 24 well plates (1x105 
cells/well) for 24 hours at 37˚C. Cells were then incubated with 
increasing concentrations of 14+ (0, 10, 50, 10, 200 µM) for 
another 24 hours in the dark at 37˚C. The compound was then 
removed and cells were washed with SFM and replenished 
with SFM. The plates were then irradiated (6.01 J (1 hour), 
12.04 J (2 hours) and 18.03 J (3 hours), using a ThorLabs LED 
(M405LP1) with an emission of 405 nm (±20nm) and power 
output of 1500 mA. The LED was fixed on a metal stand (20cm 
from base). After the irradiance, the SFM was replaced with 
serum containing medium and cells were incubated for 18 
hours. Alamar blue (Resazurin Na salt, 100 µM for 4 hours in 
SFM) was used to measure the cell viability. 
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Apoptosis and/or necrosis cell death are two defined 
1 pathways. To distinguish the cellular death pathway after the 
2 stimuli (14+ at 100µM for 24 hours with and without 1-hour 
3 405nm light irradiance) was studied using Annexin V Fluor-488 
4 and PI (Invitrogen, V13241). Briefly, C8161 melanoma cells 
5 were seeded on 6 well plate for 24 hours, then treated with or 
6 without 14+ (100µM for 24 hours in SFM), the plates were then 
7 irradiated or kept in dark for 1 hour using lamp (405nm). After 
8 which the plates were incubated with Annexin V and PI 
9 (10ug/mL and 500nM respectively) for 30 min and washed 
10 with annexin binding buffer (thrice, 5min). Cells were then 
11 fixed (formaldehyde 3.7%, 15 minute) and washed with PBS 
12 (x3, 5min). Counterstained with DAPI and imaged under a Zeiss 
13 LSM510 confocal microscope using an Achroplan water 
14 dipping objective (40X, NA 0.75, WD 2.1). 
15 Two-photon absorption cross-section imaging 
16 C8161 melanoma cells were incubated with 14+ at 100 μM 
17 concentration (in SFM) for 24 hours. Cells were then washed 
18 with PBS (x3) and fixed with 3.7% formaldehyde (15 min). 
19 Luminescence images of 14+ within were taken between 800 to 
20 1000 nm by confocal microscopy (attached to Ti-sapphire 
21 Chameleon FD900 laser) and an Achroplan objective 40X/0.75 
22 W, Scan speed of 6 r). The average optical power of each 
23 wavelength studied was altered to four different powers (5, 
24 10, 20, and 40 mW). The resultant emission images were 
25 collected at λem = 630-700nm from varied excitation 
26 wavelengths and four different power settings. To attain ideal 
27 cross-section value the emission profile was used to calculate 
28 corrected fluorescence emission intensity using ImageJ. 
29 Uptake and distribution 14+ in 3D melanoma spheroids 
30 Melanoma spheroids were formed using C8161 human 
31 melanoma cell lines using a liquid overly method as described 
32 previously.89 Briefly, an initial cell seeding density of 12K were 
33 cultured in a 96-well plate coated with agarose gel (1.5% w/v) 
34 for 10 days (at 37˚C and 5% CO2). 
35 To measure 14+ distribution through the melanoma spheroids 
36 (MCTS), spheroids after 10 days culture were removed and 
37 transferred to 35mm glass bottomed dishes (3-4 MCTS in each 
38 dish) and allowed to incubate at 37°C (5% (v/v) CO2) overnight 
39 to settle. 14+ at 100 μM concentration was incubated for a 
40 period of 24 hours. Before analysis, MCTS were washed with 
41 SFM (x3) and kept immersed in SFM during data collected upon 
42 two-photon excitation (λex = 900nm, λem = 630-700nm). A 
43 Zeiss LSM510 META upright confocal microscope, connected 
44 to a two-photon class 4 tuneable Ti-sapphire Chameleon laser 
45 (FD900,   Coherent)   and   an   Achroplan   water   dipping 40X 
46 objective lens (WD 2.1 mm, NA 0.75) was used to image the 14+ 
47 emission through the full depth of the spheroid. Optical slices 
48 were taken at 10 μm apart in each sample to create a 3D (Z- 
49 stack) construct image. The depth of penetration was between 
50 first and last fluorescence optical slice. Frame size (512 x 512) 
51 scan direction (single), scan speed (6), laser power (20mW), 
52 and detector gain (874) was kept constant for all repeats. 
53 Two-photon photo-cytotoxicity in melanoma cells 
54 Human melanoma C8161 cells were seeding on a 35 mm dish 
55 plate (5x105 cells/well). After incubation for 24 hours the cells 
56 were treated with or without 14+ at 100 μM concentration (in 
57 SFM) for 24 hours. The cells were washed with serum free 
culture medium (x3) and replenished with live and dead 
medium (propidium iodide (PI at 500 nM) and Syto-9 (2 µM) in 
SFM) for 15 minutes and through the length of time of 
experiment. The monolayer of cells was imaged for live cells 
(Syto-9, λex = 488nm (Ar-ion), λem = 500-550nm) and dead 
cells (PI, λex = 543 nm, λem = 565-615 nm). Live and dead 
image were taken from the same area (512x512 pixel) after 
every 5 minutes of irradiation at 900nm at 10 and 20 mW (scan 
speed= 6) on a marked region of interest (250x250 pixel). 
Irradiation was carried using a Ti:sapphire laser (Cameleon, 
Coherent) connected to a Zeiss confocal microscope (LSM510) 
using an Achroplan water dipping objective (40X, NA 0.75, WD 
2.1). 
 
Two-photon photo-cytotoxicity in melanoma spheroids 
Photo-cytotoxicity in 3D melanoma spheroids was also imaged 
using the same method discussed above. However, the laser 
power for irradiation was increased to 20, 40 and 60mW. After 
attaining the ideal cytotoxic response at 60mW at a single 
optical slice, spheroids were irradiated with a 60mW 900nm 2- 
photon laser using a continuous z-stack (10 µM optical slice 
apart) scan (scan speed = 6), irradiance dose though the whole 
thickness of spheroid was followed by live and dead cell scan 





Intracellular localization and uptake in melanoma cells; apoptosis 
and necrosis caused by PDT on melanoma; Two-Photon photo- 
toxicity without 14+; Imaging showing TPA-PDT of whole thickness 
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